Joseph Schwartz
Stock Analyst at Leerink Partners
(1.77)
# 1,961
Out of 4,479 analysts
116
Total ratings
32.23%
Success rate
-0.39%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.96 | +101.34% | 5 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $3.45 | +131.88% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.76 | +240.91% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.53 | +279.29% | 5 | Mar 14, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | $12 | $4.35 | +175.86% | 1 | Feb 22, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Market Perform | $23 → $7 | $2.13 | +228.64% | 2 | Feb 13, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.43 | -30.07% | 4 | Feb 9, 2024 | |
| RPHM Reneo Pharmaceuticals | Downgrades: Market Perform | $1 | $1.51 | -33.77% | 3 | Dec 15, 2023 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $3.20 | +87.50% | 4 | Aug 15, 2023 | |
| PTCT PTC Therapeutics | Initiates: Market Perform | $48 | $30.39 | +57.95% | 1 | Mar 17, 2023 | |
| PHVS Pharvaris | Maintains: Outperform | $20 → $18 | $16.85 | +6.82% | 5 | Feb 3, 2023 | |
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $30 → $20 | $11.51 | +73.76% | 4 | Feb 3, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $33 → $34 | $45.14 | -24.68% | 1 | Feb 3, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $122 → $130 | $82.22 | +58.11% | 8 | Feb 3, 2023 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $160 | $154.20 | +3.76% | 8 | Jan 20, 2023 | |
| ASND Ascendis Pharma | Maintains: Outperform | $148 → $163 | $136.27 | +19.62% | 13 | Jan 17, 2023 | |
| GOSS Gossamer Bio | Maintains: Outperform | $15 → $10 | $0.96 | +941.88% | 5 | Dec 7, 2022 | |
| PEPG PepGen | Maintains: Outperform | $40 → $33 | $16.32 | +102.21% | 2 | Nov 10, 2022 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $17 → $12 | $5.43 | +120.99% | 5 | Nov 4, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $115 → $108 | $40.96 | +163.67% | 5 | Nov 3, 2022 | |
| INSM Insmed | Maintains: Outperform | $52 → $50 | $64.50 | -22.48% | 3 | Oct 27, 2022 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $45 → $38 | $8.09 | +369.72% | 4 | Oct 20, 2022 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $36 → $39 | $45.54 | -14.36% | 1 | May 26, 2022 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $4 | $1.73 | +131.21% | 3 | May 12, 2022 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $34 → $30 | $18.38 | +63.22% | 2 | May 12, 2022 | |
| RNA Avidity Biosciences | Maintains: Outperform | $53 → $50 | $38.80 | +28.87% | 3 | May 11, 2022 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $50 → $30 | $34.59 | -13.27% | 5 | May 5, 2022 | |
| QURE uniQure | Maintains: Outperform | $71 → $56 | $4.01 | +1,296.51% | 1 | May 3, 2022 | |
| FOLD Amicus Therapeutics | Maintains: Outperform | $16 → $14 | $9.85 | +42.13% | 7 | Feb 24, 2022 | |
| FULC Fulcrum Therapeutics | Maintains: Outperform | n/a | $6.10 | - | 1 | Aug 13, 2021 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | n/a | $1.65 | - | 1 | Sep 26, 2017 |
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.96
Upside: +101.34%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $3.45
Upside: +131.88%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.76
Upside: +240.91%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.53
Upside: +279.29%
Applied Therapeutics
Feb 22, 2024
Initiates: Outperform
Price Target: $12
Current: $4.35
Upside: +175.86%
AN2 Therapeutics
Feb 13, 2024
Downgrades: Market Perform
Price Target: $23 → $7
Current: $2.13
Upside: +228.64%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.43
Upside: -30.07%
Reneo Pharmaceuticals
Dec 15, 2023
Downgrades: Market Perform
Price Target: $1
Current: $1.51
Upside: -33.77%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.20
Upside: +87.50%
PTC Therapeutics
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $30.39
Upside: +57.95%
Pharvaris
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $16.85
Upside: +6.82%
KalVista Pharmaceuticals
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.51
Upside: +73.76%
Ionis Pharmaceuticals
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $45.14
Upside: -24.68%
BioMarin Pharmaceutical
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $82.22
Upside: +58.11%
Sarepta Therapeutics
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $154.20
Upside: +3.76%
Ascendis Pharma
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $136.27
Upside: +19.62%
Gossamer Bio
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.96
Upside: +941.88%
PepGen
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $16.32
Upside: +102.21%
Aurinia Pharmaceuticals
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $5.43
Upside: +120.99%
Ultragenyx Pharmaceutical
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $40.96
Upside: +163.67%
Insmed
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $64.50
Upside: -22.48%
Travere Therapeutics
Oct 20, 2022
Maintains: Outperform
Price Target: $45 → $38
Current: $8.09
Upside: +369.72%
Crinetics Pharmaceuticals
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $45.54
Upside: -14.36%
InflaRx
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.73
Upside: +131.21%
Edgewise Therapeutics
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $18.38
Upside: +63.22%
Avidity Biosciences
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $38.80
Upside: +28.87%
Protagonist Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $34.59
Upside: -13.27%
uniQure
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $4.01
Upside: +1,296.51%
Amicus Therapeutics
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.85
Upside: +42.13%
Fulcrum Therapeutics
Aug 13, 2021
Maintains: Outperform
Price Target: n/a
Current: $6.10
Upside: -
ProQR Therapeutics
Sep 26, 2017
Maintains: Outperform
Price Target: n/a
Current: $1.65
Upside: -